Skip to content

By Daniel DeVido, PhD, Director of Strategic Business Development, FUJIFILM Biotechnologies

cell rendering
July 14, 2023

Fast-Tracking Development of MSC-Based Cell and Extracellular Vesicle Therapies Through a Strategic Partnership

FUJIFILM Biotechnologies can help fast-track development of your MSC-Based Cell Therapies and Extracellular Vesicle Therapies Through our Strategic Partnership with RoosterBio.

May 4, 2023

Practical Considerations for your Sub-contracted Process Characterization (PC) Study

Subcontracting a Process Characterization (PC) study can be an expedient and practical undertaking for a biopharmaceutical company.

April 12, 2023

Enhanced Paveway™ PLUS Selects Expression Organisms Based on Titer Plus Quality

Launched in 2007, our core microbial expression system Paveway™ has offered industry leading titers by enabling lead strain selection based on product titer in six…

January 26, 2023

Paveway™ PLUS Microbial Expression System for the Efficient Production of Therapeutic Proteins

Paveway™ is an innovative expression system in Escherichia coli (E. coli) that enables the creation of novel recombinant strains where the lead strain selection is…

January 9, 2023

Advancing Cell and Gene Therapies Through Closed Aseptic Processes

Read about the benefits of closed aseptic processes in cell and gene therapy manufacturing.

October 28, 2022

Oncolytic Viruses Development and cGMP Manufacturing

FUJIFILM Biotechnologies offers preclinical, clinical, commercial GMP process development and manufacturing for oncolytic viruses, cancer viral vector vaccines and therapies in our global CDMO network.

October 10, 2022

The Changing Vaccine Development Landscape

Learn how the vaccines landscape is rapidly changing and what types of vaccines are now dominating the clinical development pipeline and biologics manufacturing.

July 14, 2022

Webinar: Biomanufacturing Strategies for Meeting Commercial Demand

Learn more with Biomanufacturing Strategies for Meeting Commercial Demand First Name(Required)Last Name(Required)Company Name(Required)Country(Required)United StatesUnited KingdomAfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius...

June 10, 2022

An AAV Platform Advancing Successful Viral Vector Based Therapeutics

FUJIFILM Biotechnologies’ AAV platform is designed to support the timely and cost-effective development and manufacture of viral-based therapies.